IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Seneca House Advisors

Seneca House Advisors lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.0% during the fourth quarter, Holdings Channel reports. The fund owned 916 shares of the company’s stock after selling 48 shares during the quarter. Seneca House Advisors’ holdings in IDEXX Laboratories were worth $379,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Frank Rimerman Advisors LLC purchased a new position in shares of IDEXX Laboratories during the 2nd quarter worth $253,000. Public Sector Pension Investment Board increased its stake in IDEXX Laboratories by 67.6% in the second quarter. Public Sector Pension Investment Board now owns 3,078 shares of the company’s stock valued at $1,500,000 after purchasing an additional 1,241 shares during the last quarter. Marshall Wace LLP lifted its position in IDEXX Laboratories by 2.5% during the second quarter. Marshall Wace LLP now owns 20,500 shares of the company’s stock worth $9,988,000 after buying an additional 500 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its stake in IDEXX Laboratories by 60.5% in the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 15,914 shares of the company’s stock worth $7,753,000 after buying an additional 5,998 shares during the last quarter. Finally, APG Asset Management US Inc. boosted its stake in IDEXX Laboratories by 10.8% in the 2nd quarter. APG Asset Management US Inc. now owns 52,577 shares of the company’s stock worth $25,048,000 after buying an additional 5,139 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several research analyst reports. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Piper Sandler reaffirmed a “neutral” rating and issued a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. JPMorgan Chase & Co. dropped their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Finally, Barclays cut their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a report on Monday, November 4th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $523.86.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now owns 905 shares in the company, valued at approximately $380,498.20. The trade was a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Up 0.4 %

Shares of NASDAQ IDXX opened at $432.34 on Friday. The stock has a fifty day moving average price of $423.28 and a 200 day moving average price of $456.85. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39. The company has a market cap of $35.40 billion, a P/E ratio of 41.69, a P/E/G ratio of 3.63 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. The business had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.53 earnings per share. Research analysts anticipate that IDEXX Laboratories, Inc. will post 10.44 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.